



## **Inimex Selected to Present at Two San Francisco Venture Financing Conferences**

### **FOR IMMEDIATE RELEASE**

#### **Vancouver, B.C., Canada – October 17, 2005.**

Inimex Pharmaceuticals, Inc. is pleased to announce that it will present at two major life science venture conferences in San Francisco, CA this fall: the BIO InvestorForum (October 19-20) and the National Conference on Biotechnology Ventures (November 14-16).

Inimex President and CEO Dr. John North will provide an update on recent advances at Inimex, including demonstration of proof of concept for Inimex' lead product in several preclinical models of bacterial disease. Dr. North will also discuss Inimex' role as a strategic partner in a consortium of researchers receiving a grant offer from the Foundation for the National Institutes of Health (FNIH) as part of the Grand Challenges in Global Health initiative toward world health issues made by the Bill and Melinda Gates Foundation and the FNIH.

According to North, "There has been considerable interest in the innate immunity space in the last year, including IPOs and major pharma deals by first generation innate immunity companies Anadys Pharmaceuticals and Coley Pharmaceuticals, as well as the acquisition of Corixa Corporation by GlaxoSmithKline. Inimex technology represents the 'next wave' of innate immunity drugs. Our drugs fill the gap between vaccines and antibiotics due to their rapid action and broad spectrum activity, which is uncomplicated by drug resistance. Inimex drugs will be an important addition to the armamentarium of the infectious disease clinician, especially in light of antibiotic resistance and the growing numbers of immune suppressed patients."

Inimex is currently raising a Series B round of venture financing to advance its lead program for hospital infections into clinical development and its inflammatory disease program into formal preclinical evaluation. In 2004 the Company announced a US\$6.8 million Series A venture financing with leading Canadian investors, including the Business Development Bank of Canada, the Working Opportunity Fund (EVCC) Ltd., managed by GrowthWorks Capital, the Canadian Medical Discoveries Fund, Inc. and BC Medical Innovations Fund, Inc., advised by MDS Capital, Inc., BC Advantage Funds (EVCC) Ltd. and British Columbia Discovery Fund (VCC), Inc.

#### About Inimex Pharmaceuticals, Inc.

Inimex Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to the discovery, development, and commercialization of new medicines based on the selective modulation of the innate immune response. Inimex' first in class products show promise for the safe and effective treatment of a broad spectrum of serious unmet medical needs in infectious disease, cancer, and inflammatory disease.

For further information, please visit the company website, [www.inimexpharma.com](http://www.inimexpharma.com) or contact:

Roger Graham, Ph.D.  
Vice President, Corporate Development  
Inimex Pharmaceuticals, Inc.  
Tel: 604-225-2251  
Fax: 604-225-2257  
[rgraham@inimexpharma.com](mailto:rgraham@inimexpharma.com)